Bafna Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 40.00 Cr
- Paid Up Capital ₹ 23.66 Cr
- Company Age 29 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 56.00 Cr
- Satisfied Charges ₹ 159.66 Cr
- Revenue Growth 35.97%
- Profit Growth 120.11%
- Ebitda 40.03%
- Net Worth 16.82%
- Total Assets 43.59%
About Bafna Pharmaceuticals
Bafna Pharmaceuticals Limited (BPL) is a leading Public Limited Indian Non-Government Company incorporated in India on 28 March 1995 and has a history of 29 years and ten months. Its registered office is in Chennai, Tamil Nadu, India.
It is listed on the Bombay Stock Exchange(BSE) under the ticker symbol 532989 and on the National Stock Exchange(NSE) under BAFNAPH.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 40.00 Cr and a paid-up capital of Rs 23.66 Cr.
The company currently has active open charges totaling ₹56.00 Cr. The company has closed loans amounting to ₹159.66 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Bafna Pharmaceuticals Limited India are Mahaveer Bafna as Ceo, Vishnu Kuppa as Company Secretary, and Melagiri Sridhar as Cfo. Krishna Yeachuri, Shanmugam Hemalatha, Sundaresan Palamadai, and Four other members serve as directors at the Company.
Company Details
-
Location
Chennai, Tamil Nadu, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
Industry
Who are the key members and board of directors at Bafna Pharmaceuticals?
Executive Team (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mahaveer Bafna
|
CEO | Current | |
|
Vishnu Kuppa
|
Company Secretary | Current | |
|
Melagiri Sridhar
|
CFO | Current |
Board Members (7)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
|
Krishna Yeachuri
|
Director | 26-Jun-2023 | Current |
|
Shanmugam Hemalatha
|
Whole-Time Director | 10-Sep-2020 | Current |
|
Sundaresan Palamadai
|
Director | 25-Jun-2020 | Current |
|
Akila Raju
|
Director | 10-Sep-2020 | Current |
|
Vinayak Dendukuri
|
Whole-Time Director | 26-Jun-2023 | Current |
|
Ravichandran Chitra
|
Director | 12-Nov-2020 | Current |
Financial Performance of Bafna Pharmaceuticals.
Bafna Pharmaceuticals Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 35.97% increase. The company also saw a substantial improvement in profitability, with a 120.11% increase in profit. The company's net worth Soared by an impressive increase of 16.82%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Bafna Pharmaceuticals?
In 2023, Bafna Pharmaceuticals had a promoter holding of 90.00% and a public holding of 10.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Xuvi Technology Labs Private LimitedRavichandran Chitra is a mutual person
-
Hvcs Corporate Solutions Private LimitedSundaresan Palamadai is a mutual person
-
Chintalapati Holdings Private LimitedAkila Raju is a mutual person
-
Skanda Aerospace Private LimitedAkila Raju is a mutual person
-
Sai Wardha Power Generation Private LimitedAkila Raju and Upendar Reddy are mutual person
-
Tanjore Power LimitedKrishna Yeachuri and Upendar Reddy are mutual person
Charges (Loans)
₹56.00 Cr
₹159.66 Cr
Charges Breakdown by Lending Institutions
- Others : 56.00 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 21 Feb 2024 | Others | ₹12.00 Cr | Open |
| 30 Nov 2023 | Others | ₹12.00 Cr | Open |
| 05 Jun 2023 | Others | ₹2.00 Cr | Open |
| 27 Oct 2021 | Others | ₹5.00 Cr | Open |
| 27 Oct 2021 | Others | ₹25.00 Cr | Open |
How Many Employees Work at Bafna Pharmaceuticals?
Bafna Pharmaceuticals has a workforce of 354 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Bafna Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Bafna Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
